12:00 AM
 | 
Apr 01, 2013
 |  BC Week In Review  |  Company News  |  Other News

Vivalis, GlaxoSmithKline, Texas A&M University System, U.S. Department of Health and Human Services infectious, biomanufacturing news

GlaxoSmithKline and the university announced that HHS has approved the establishment of a $91 million influenza-vaccines manufacturing facility in Bryan-College Station, Texas. The pharma said the center will allow it the ability to eventually manufacture influenza vaccine based on the EB66 cell line, which is derived from duck embryonic...

Read the full 224 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >